Breast CancerNCT03475992
Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.
A study testing Low-power microwave breast imaging system in people with Breast Cancer and Breast Cyst, run by MVG Industries SAS at 1 site in Ireland.
Trial summary
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation. Microwave imaging is an emerging imaging modality for the early detection of the breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Breast Cyst
- What is being tested?
- Low-power microwave breast imaging system
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteIreland
- Study dates
- 10 Oct 2018to 7 May 2020
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
- Subject must have attended the Symptomatic Breast Unit with a palpable breast lump
- Subjects must have had a mammogram in the clinical assessment period (≤ 6 weeks before the microwave breast investigation)
- Subjects must be able to comfortably lie reasonably still in a prone position for up to 15 minutes
- Subjects with bra size larger than 32B and cup size larger or equal to B.
- Subjects whose breast size is adapted to the cylindrical container of the MBI system with sufficient margin to allow the presence of transition liquid around the breast. Final decision to be taken by the physicians based on their judgement.
Who cannot join
- Subjects unable to provide written informed consent
- Subjects who are pregnant or breast-feeding
- Subjects who have had previous surgery to the breast
- Subjects who have previously received chemotherapy or radiotherapy to the breast
- Subjects who have had a breast biopsy less than two weeks prior to imaging
- Subjects with any active or metallic implant (e.g. cardiac pacemaker, stents, internal cardiac defibrillator, cardiac resynchronisation device, nerve stimulator…), or subjects bearing any non-removable metallic object (e.g. piercing) on their torso
Show all 13Show fewer
- Post-biopsy patients whose breast tissue is not healed sufficiently for the imaging procedure, in the opinion of the investigator
- Patients who have had or plan to have a breast cyst aspiration before MBI.
- Subjects with significant co-morbidities which, in the opinion of the investigator, may influence the result of the study
- Subjects with prior or concurrent malignancy
- Subjects under the age of 18 years old
- Subjects with evidence of inflammation and/or erythema of the breast as well as any subjects who have a break in the skin which would be in contact with the coupling fluid
- Subjects who would be unsuitable for an MBI scan, unlikely to attend a follow up visit, or would otherwise be unsuitable for such an investigation, in the opinion of the Investigator
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pilot Clinical Evaluation of a Microwave Imaging System for Early Breast Cancer Detection
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
Microwave imaging is an emerging imaging modality for the early detection of the breast cancer. The physical basis of microwave imaging is the dielectric contrast between healthy and cancerous breast tissues at microwave frequencies. Microwave imaging can potentially be used for monitoring neoadjuvant chemotherapy treatment, breast health monitoring, and for routine screening and diagnosis of the breast cancer at the early-stage. The non-invasive and the non-ionizing characteristics of microwaves should allow for frequent scans of the breast using microwave imaging, unlike X-ray mammography. In addition to safety, microwave imaging does not require uncomfortable breast compression and it is potentially a lower-cost modality.
Read more
This is a first-in-human clinical test of the investigational device, which has been so far tested only with experimental phantoms modelling the human female breast.
The clinical data that will be collected in the context of this study is intended to provide early safety information for the investigational medical imaging device. In addition, this exploratory data will guide the refinement of the device hardware and the imaging algorithm design, before decision to proceed (or not) with further clinical tests.
Furthermore, this study will be used to guide sample size calculation for a subsequent study designed to evaluate efficacy should that appear warranted once this study is completed.
Read the detailed description
This is a single-site early-phase pilot clinical study, taking place at Galway University Hospital/HRB Clinical Research Facility, Galway.
Patients will have a conventional history and breast examinations (Mammogram and / or Ultrasound and Clinical assessment) performed by the physician, as per normal practice in the Symptomatic Breast Unit of University Hospital Galway.
If patients are interested in the study, provide written informed consent and are deemed eligible, they will attend the Clinical Research Facility Galway for a Microwave Breast Imaging (MBI) scan. The data from the scan will be collected and stored securely. Patients will be followed up 7-21 days after the microwave breast investigation or before surgery, whichever comes first. Patients will be assessed for their experience of the microwave breast investigation, and for any adverse events.
The investigational medical imaging device consists of two subsystems, both performing a non-invasive examination:
- the Microwave Breast Imaging subsystem (MBI subsystem);
- the Optical Breast Contour Detection subsystem (OBCD subsystem);
The MBI subsystem is an active device which uses non-ionizing radiation. It illuminates the breast with low-power electromagnetic waves in the microwave frequency spectrum, which penetrate the breast under examination. The subsystem collects the scattered electromagnetic waves and recovers useful information on the breast tissue consistency, given the dielectric contrast of these tissues.
Multi-static radar detection technology is employed in the MBI subsystem for breast image formation.The well-established Microwave Vision Group (MVG) technology for fast antenna measurement, using multiple sensors in a vertical arch configuration, has been transposed to a horizontal arch of sensors. In addition, vertical translation of the horizontal arch has been enabled, such that 3D multi-static short-range radar imaging is possible.
The sensors are in contact with a cylindrical container filled with a liquid; the so-called coupling liquid has been designed to have electromagnetic (EM) properties appropriately selected such that the EM wave penetration in the breast is maximized.
During the MBI scan, the patient is lying in a face down position on a special bed, integrated with the MBI subsystem. The breast under examination is immersed in the coupling liquid, through a dedicated circular opening of the bed. The breast is then scanned. This vertical scan takes approximately 10-15 minutes to complete, depending on the size of each breast.
In order to compute the required volume of coupling liquid, such that the container of the MBI subsystem is optimally filled after immersion of the breast, a simple process for optical assessment of the total volume of the breast takes place just before starting the MBI scan.
The Optical Breast Contour Detection (OBCD) subsystem serves to provide the total volume of the breast, and also its external contour, as a priori information to the MBI subsystem. The OBCD subsystem consists of a 3D optical camera placed below the examination table, at a distance of several tens of centimetres below the breast. An azimuthal scan of the 3D camera permits to reconstruct the external surface of the breast.
In order for the breast contour to be a useful a priori information for the MBI subsystem, it is important that the patient is lying in the same face down position during both the MBI and OBCD scans. Thus, an identical examination table, as the one integrated with the MBI subsystem, is also integrated with the OBCD subsystem. During the OBCD scan, the patient is lying on the examination table, with her breast under examination inserted in the circular opening of the examination table. For this scan, there is no coupling liquid; the breast is in the air, hanging below the examination table.
Both the breast bearing the palpable lump and the contralateral breast will be scanned. The contralateral breast scan will serve as control in the data analysis.
The MBI scan duration of each breast should not exceed 15 minutes. The recorded data will be checked and in the case of non-optimal positioning of the patient, the scan may be repeated.
It is expected that the duration of the microwave breast investigation (including OBCD scan of both breasts for breast volume assessment, preparation of the MBI subsystem, MBI scan of both breasts, and data verification) should not exceed 1 hour. If the Data Quality Check suggests repetition of the MBI scan, and upon agreement by the patient, the total duration of the microwave breast investigation will be extended.
The written radiology reports from conventional imaging will be acquired and used to evaluate the performance of the MBI subsystem in terms of detecting and estimating the size and consistency of the breast lump.
MBI data analysis will be performed off-line, at MVG premises (France), and is expected to be completed few months after the end-date of data collection. Following the assessment of the MBI results by the medical experts involved in the study, a decision will be made regarding the potential of this emerging imaging modality and the interest in proceeding with clinical studies involving larger sample sizes. Based on these results, MVG will decide and plan actions for refinement of the system, towards an upgraded version to be used for potential future tests with a more significant impact.
- Conditions
- Breast Cancer, Breast Cyst
- Being tested
- Low-power microwave breast imaging system
- Medical subject headings
- Breast Neoplasms, Breast Cyst
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-power microwave breast imaging systemDevice
Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
| Study group | Role | What they receive |
|---|---|---|
| Pre-diagnosed breast cancer | Experimental | Low-power microwave breast imaging system.
Core needle biopsy performed ≥14 days before the microwave breast investigation Receives: Device: Low-power microwave breast imaging system |
| Pre-diagnosed breast cyst | Experimental | Low-power microwave breast imaging system.
No prior biopsy Receives: Device: Low-power microwave breast imaging system |
| Pre-diagnosed benign lesion | Experimental | Low-power microwave breast imaging system.
Core needle biopsy performed ≥14 days before the microwave breast investigation Receives: Device: Low-power microwave breast imaging system |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Serious Adverse Events, Directly Related to Normal Functioning of the Device
To provide early safety information for the proposed investigational medical imaging device.
Measured: Through study completion, up to 21 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2018
- Study start10 Oct 2018
- Primary completion7 May 2020
- Study completion7 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- The study is performed on 3 groups of patients: * Group 1: 15 patients with pre-diagnosed breast cancer (core needle biopsy performed ≥14 days before the microwave breast investigation). * Group 2: 10 patients with breast cyst. No prior biopsy * Group 3: 5 patients with pre-diagnosed benign lesion (core needle biopsy performed ≥14 days before the microwave breast investigation).
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- MVG Industries SAS
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- HRB Clinical Research Facility Galway
- Responsible party
- Sponsor
- Investigators
- Michael Kerin, Prof., Principal investigator, Galway University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03475992
- Sponsor's protocol ID
- TN.32.1.17.SATF
- Status last verified
- May 2021
- First submitted
- 12 Mar 2018
- Last updated
- 7 Jun 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Clinical Evaluation of a Microwave Imaging System for Early Breast Cancer Detection
- ClinicalTrials.gov ID
- NCT03475992
- Acronym / sponsor ID
- TN.32.1.17.SATF
- Conditions
- Breast Cancer, Breast Cyst
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- MVG Industries SASIndustry (pharma, biotech, devices)
- Collaborators
- HRB Clinical Research Facility Galway
- Study start
- 10 Oct 2018 (actual)
- Primary completion
- 7 May 2020 (actual)
- Study completion
- 7 May 2020 (actual)
- First posted
- 23 Mar 2018 (actual)
- Results
- Posted 7 Jun 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
Microwave imaging is an emerging imaging modality for the early detection of the breast cancer. The physical basis of microwave imaging is the dielectric contrast between healthy and cancerous breast tissues at microwave frequencies. Microwave imaging can potentially be used for monitoring neoadjuvant chemotherapy treatment, breast health monitoring, and for routine screening and diagnosis of the breast cancer at the early-stage. The non-invasive and the non-ionizing characteristics of microwaves should allow for frequent scans of the breast using microwave imaging, unlike X-ray mammography. In addition to safety, microwave imaging does not require uncomfortable breast compression and it is potentially a lower-cost modality.
This is a first-in-human clinical test of the investigational device, which has been so far tested only with experimental phantoms modelling the human female breast.
The clinical data that will be collected in the context of this study is intended to provide early safety information for the investigational medical imaging device. In addition, this exploratory data will guide the refinement of the device hardware and the imaging algorithm design, before decision to proceed (or not) with further clinical tests.
Furthermore, this study will be used to guide sample size calculation for a subsequent study designed to evaluate efficacy should that appear warranted once this study is completed.
Detailed description
This is a single-site early-phase pilot clinical study, taking place at Galway University Hospital/HRB Clinical Research Facility, Galway.
Patients will have a conventional history and breast examinations (Mammogram and / or Ultrasound and Clinical assessment) performed by the physician, as per normal practice in the Symptomatic Breast Unit of University Hospital Galway.
If patients are interested in the study, provide written informed consent and are deemed eligible, they will attend the Clinical Research Facility Galway for a Microwave Breast Imaging (MBI) scan. The data from the scan will be collected and stored securely. Patients will be followed up 7-21 days after the microwave breast investigation or before surgery, whichever comes first. Patients will be assessed for their experience of the microwave breast investigation, and for any adverse events.
The investigational medical imaging device consists of two subsystems, both performing a non-invasive examination:
- the Microwave Breast Imaging subsystem (MBI subsystem);
- the Optical Breast Contour Detection subsystem (OBCD subsystem);
The MBI subsystem is an active device which uses non-ionizing radiation. It illuminates the breast with low-power electromagnetic waves in the microwave frequency spectrum, which penetrate the breast under examination. The subsystem collects the scattered electromagnetic waves and recovers useful information on the breast tissue consistency, given the dielectric contrast of these tissues.
Multi-static radar detection technology is employed in the MBI subsystem for breast image formation.The well-established Microwave Vision Group (MVG) technology for fast antenna measurement, using multiple sensors in a vertical arch configuration, has been transposed to a horizontal arch of sensors. In addition, vertical translation of the horizontal arch has been enabled, such that 3D multi-static short-range radar imaging is possible.
The sensors are in contact with a cylindrical container filled with a liquid; the so-called coupling liquid has been designed to have electromagnetic (EM) properties appropriately selected such that the EM wave penetration in the breast is maximized.
During the MBI scan, the patient is lying in a face down position on a special bed, integrated with the MBI subsystem. The breast under examination is immersed in the coupling liquid, through a dedicated circular opening of the bed. The breast is then scanned. This vertical scan takes approximately 10-15 minutes to complete, depending on the size of each breast.
In order to compute the required volume of coupling liquid, such that the container of the MBI subsystem is optimally filled after immersion of the breast, a simple process for optical assessment of the total volume of the breast takes place just before starting the MBI scan.
The Optical Breast Contour Detection (OBCD) subsystem serves to provide the total volume of the breast, and also its external contour, as a priori information to the MBI subsystem. The OBCD subsystem consists of a 3D optical camera placed below the examination table, at a distance of several tens of centimetres below the breast. An azimuthal scan of the 3D camera permits to reconstruct the external surface of the breast.
In order for the breast contour to be a useful a priori information for the MBI subsystem, it is important that the patient is lying in the same face down position during both the MBI and OBCD scans. Thus, an identical examination table, as the one integrated with the MBI subsystem, is also integrated with the OBCD subsystem. During the OBCD scan, the patient is lying on the examination table, with her breast under examination inserted in the circular opening of the examination table. For this scan, there is no coupling liquid; the breast is in the air, hanging below the examination table.
Both the breast bearing the palpable lump and the contralateral breast will be scanned. The contralateral breast scan will serve as control in the data analysis.
The MBI scan duration of each breast should not exceed 15 minutes. The recorded data will be checked and in the case of non-optimal positioning of the patient, the scan may be repeated.
It is expected that the duration of the microwave breast investigation (including OBCD scan of both breasts for breast volume assessment, preparation of the MBI subsystem, MBI scan of both breasts, and data verification) should not exceed 1 hour. If the Data Quality Check suggests repetition of the MBI scan, and upon agreement by the patient, the total duration of the microwave breast investigation will be extended.
The written radiology reports from conventional imaging will be acquired and used to evaluate the performance of the MBI subsystem in terms of detecting and estimating the size and consistency of the breast lump.
MBI data analysis will be performed off-line, at MVG premises (France), and is expected to be completed few months after the end-date of data collection. Following the assessment of the MBI results by the medical experts involved in the study, a decision will be made regarding the potential of this emerging imaging modality and the interest in proceeding with clinical studies involving larger sample sizes. Based on these results, MVG will decide and plan actions for refinement of the system, towards an upgraded version to be used for potential future tests with a more significant impact.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- The study is performed on 3 groups of patients: * Group 1: 15 patients with pre-diagnosed breast cancer (core needle biopsy performed ≥14 days before the microwave breast investigation). * Group 2: 10 patients with breast cyst. No prior biopsy * Group 3: 5 patients with pre-diagnosed benign lesion (core needle biopsy performed ≥14 days before the microwave breast investigation).
| Arm | Type | Receives |
|---|---|---|
| Pre-diagnosed breast cancer | Experimental | Device: Low-power microwave breast imaging systemLow-power microwave breast imaging system. Core needle biopsy performed ≥14 days before the microwave breast investigation |
| Pre-diagnosed breast cyst | Experimental | Device: Low-power microwave breast imaging systemLow-power microwave breast imaging system. No prior biopsy |
| Pre-diagnosed benign lesion | Experimental | Device: Low-power microwave breast imaging systemLow-power microwave breast imaging system. Core needle biopsy performed ≥14 days before the microwave breast investigation |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
- Subject must have attended the Symptomatic Breast Unit with a palpable breast lump
- Subjects must have had a mammogram in the clinical assessment period (≤ 6 weeks before the microwave breast investigation)
- Subjects must be able to comfortably lie reasonably still in a prone position for up to 15 minutes
- Subjects with bra size larger than 32B and cup size larger or equal to B.
Key exclusion criteria (13 listed)
- Subjects unable to provide written informed consent
- Subjects who are pregnant or breast-feeding
- Subjects who have had previous surgery to the breast
- Subjects who have previously received chemotherapy or radiotherapy to the breast
- Subjects who have had a breast biopsy less than two weeks prior to imaging
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low-power microwave breast imaging systemInvestigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump | Device | Pre-diagnosed benign lesion, Pre-diagnosed breast cancer, Pre-diagnosed breast cyst |
Primary outcome
Number of Serious Adverse Events, Directly Related to Normal Functioning of the Device
Time frame: Through study completion, up to 21 days
To provide early safety information for the proposed investigational medical imaging device.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- The manufacturer of the trialed investigational medical device and sponsor of the clinical investigationLink provided by the sponsor.
- The investigational siteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Not yet recruitingPhase 2
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Breast Neoplasms, Advanced Breast Cancer
RecruitingPhase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Active, not recruitingPhase 2
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Breast Cancer Stage IV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Kerin, Prof. principal investigator
Galway University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low-power microwave breast imaging system in people with Breast Cancer and Breast Cyst, run by MVG Industries SAS at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Serious Adverse Events, Directly Related to Normal Functioning of the Device (time frame: Through study completion, up to 21 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2021.